Study progress of EGFR-targeting antibody related biomarkers
10.3760/cma.j.issn.1006-9801.2009.08.029
- VernacularTitle:表皮生长因子受体单抗相关生物标志研究进展
- Author:
Huilong LIU
;
Duanqi LIU
- Publication Type:Journal Article
- Keywords:
Receptor,epidermal growth factor;
,Biological markers
- From:
Cancer Research and Clinic
2009;21(8):501-503
- CountryChina
- Language:Chinese
-
Abstract:
With the emerging of EGFR-targeting antibody, there is a new choice for malignant tumors. Several studies indicate that cetuximab combined with chemotherapy have a role in the first-line treatment of metastatic colorectal and lung cancer, with a 10% to 20% absolute increase in response rates reported. But, cosily price and partly responsive rate restrict the reasonable use of the drug. If the predictive biomarker works, clinician can identify patients who can benefit from the regimen and relieve the economic and toxic burden of null patients and avoid wasting time and money. The study progress of the biomarkers related to EGFR-targeting antibody was reviewed.
